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Abstract The objective of this study was to evaluate the in
vitro and in vivo efficacies of linezolid (35 mg/kg/5 h),
vancomycin (60 mg/kg/5 h), imipenem (30 mg/kg/5 h),
linezolid+imipenem,linezolid+vancomycinandvancomycin+
imipenem against two clinical Staphylococcus aureus isolates
with reduced susceptibility to glycopeptides using time–kill
curves and the murine peritonitis model. Time–kill curves
were performed over 24 h. For the murine peritonitis model,
peritonitis was induced by the intraperitoneal inoculation of
10
8 CFU/ml of each bacterial strain. Four hours later (0 h),
the mice were randomly assigned to a control group or to
therapeutic groups receiving subcutaneous treatment for 25 h.
Bacterial counts in peritoneal fluid, bacteraemia and mortality
rates were determined. The time–kill curves showed that the
addition of linezolid to imipenem yielded synergistic results
after 24 h. The addition of linezolid decreased vancomycin
activity. In the animal model, vancomycin and linezolid
monotherapies produced comparable bacterial decreases in
mice infected with each strain but linezolid achieved higher
rates of blood sterilisation. Linezolid tested either in mono-
therapy or in combination showed similar efficacy against
both strains in terms of bacterial killing, number of negative
blood cultures and survival. Linezolid and vancomycin were
moderately bactericidal and similar in efficacy against
glycopeptide-intermediate or -resistant S. aureus. Linezolid
combinations, as effective as linezolid tested alone, could be
considered as alternative options for the treatment of
glycopeptide-intermediate S. aureus (GISA) infections.
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is the
most important cause of antibiotic-resistant healthcare-
associated infections [1]. In addition, clinical isolates of
S. aureus with heterogeneous resistance to vancomycin
(hGISA) and, more rarely, glycopeptide-intermediate-
resistant strains (GISA) have emerged worldwide over the
past several years [2–4].
Reduced vancomycin and teicoplanin activities against
hGISA and GISA isolates have been reported in experimental
studies [5–7], while in the clinical setting, vancomycin has
appeared to be sub-optimal in deep-seated and difficult-to-
treat infections caused by these strains [7, 8]. Furthermore,
the antagonistic effect or false synergy showed by in vitro
studies with the combination of glycopeptides and β-lactams
refuses its use as a potentially promising alternative to
glycopeptide monotherapy [9, 10]. The oxazolidinone line-
zolid, one of the new treatment options for multidrug-
resistant Gram-positive bacteria [11–13], shows high in vitro
activity against resistant staphylococcal strains [13, 14]. In
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DOI 10.1007/s10096-010-1007-ypatients with MRSA infections, linezolid has shown compa-
rable efficacy to vancomycin [15, 16]. Moreover, it shows
excellent oral bioavailability and does not require dose
adjustment for renal insufficiency [14]. Its unique mechanism
of action by inhibiting ribosomal protein synthesis at an early
stage of bacterial replication leads to the absence of cross-
resistance with other antimicrobials [15]. Although linezolid-
nonsusceptible strains are unusual [17], long courses of
oxazolidinone therapy could select resistant mutants [18, 32];
hence, the use of a combined strategy might be considered in
clinical practice. To date, the efficacy of linezolid as part of a
combination has been studied against MRSA strains, but
very few data has been reported against hGISA or GISA
strains [19, 20]. Linezolid plus β-lactams exhibited bacteri-
cidal and synergistic activity against MRSA and hGISA
strains in experimental models of endocarditis and meningitis
[19]. Linezolid plus rifampicin was an effective prophylactic
regimen for preventing staphylococcal prosthetic vascular
graft infection, although the combination did not show higher
efficacy compared to linezolid monotherapy [20].
We aimed to evaluate and compare the efficacies of
linezolid alone and in combination with either vancomycin
or imipenem against two S. aureus strains with reduced
susceptibility to glycopeptides.
Materials and methods
Bacterial strains
Two clinical isolates of S. aureus with different degrees of
resistance to glycopeptides were included: an hGISA strain
isolated in our hospital and belonging to the Iberian clone,
growing on 4 mg/l vancomycin Mueller–Hinton plates with
a sub-population frequency of 3.6×10
−6 CFU/ml (this
strain was equivalent to the Mu3 heteroresistant strain)
[8], and a GISA strain (Mu50, ATCC 700699) reported as
the first GISA strain [3]. Minimum inhibitory concentra-
tions (MICs, mg/l), determined using the Etest and the
macrodilution method [21], were as follows for the hGISA
strain: cloxacillin, 1,024; cefotaxime, 1,024; teicoplanin 8;
vancomycin (VAN), 2; linezolid (LZD), 1; and imipenem
(IMP), 32. MICs for the GISA strain were: cloxacillin,
1,024; cefotaxime, 2,048; teicoplanin, 16; VAN, 8; LZD, 2;
and IMP, 64.
In vitro time–kill studies
The bactericidal activities of the drugs were tested in glass
tubes containing Mueller–Hinton broth and a final inocu-
lum of 1×10
5 to 1×10
6 CFU/ml [21]. Linezolid (Pfizer,
Madrid, Spain), imipenem–cilastatin (Merck, Sharp &
Dohme, Madrid, Spain) and vancomycin (Normon, Madrid,
Spain) were provided by the manufacturers. Antibiotics
were tested for a range of concentrations according to their
MICs and their achievable levels in human serum: linezolid
concentrations ranging from 1/4× to 8× MIC, vancomycin
concentrations ranging from 1/4× to 1× MIC, imipenem
levels from 1/8× to 1× MIC, as well as concentrations of
1/4×, 1/2× and 1× MIC of each drug in combination. In all
experiments, growth control was assessed using an extra
tube without antibiotic. At 0, 6 and 24 h of incubation,
aliquots of 100 μl were taken from each tube to perform
direct and 10-fold dilutions, and were cultured onto 5%
sheep blood agar plates (SBA) at 37°C for 24 h. Experi-
ments were performed in duplicate. The following effects
were studied in combinations after 24 h of incubation: a
bactericidal effect was defined as a decrease in the initial
inoculum of ≥3 log10CFU/ml; the synergy of a combination
was defined as a >2 log10CFU/ml reduction over the most
active agent alone, with one of the drugs at subinhibitory
concentration; an indifferent effect was defined as <1 log
(increase or decrease) in killing.
Pharmacokinetics
Pharmacokinetic studies were performed to select dose
regimens that result in serum concentrations similar to those
found in humans [6, 22]. Groups of 21 healthy mice were
used for each pharmacokinetic study. A single weight-
adjusted antibiotic dose was administered subcutaneously
(sc) to each animal. At different time points, sets of three
animals were anaesthetised intraperitoneally (ip), and blood
samples (0.5 ml) were obtained by an intracardiac puncture.
Blood was centrifuged and serum stored at −80°C. Pharma-
cokinetic and pharmacodynamic parameters were obtained
by a computer-assisted method (PK Functions for Microsoft
Excel; Usansky, Desai and Tang-Liu, Pharmacokinetics and
Drug Metabolism Dept., Allergan, Irvine, CA 92606, USA)
after the determination of antibiotic concentrations over time.
Based on the obtained parameters, the final selected doses
were: vancomycin 60 mg/kg every 5 h (300 mg/kg/day),
linezolid 35 mg/kg every 5 h (175 mg/kg/day) and imipenem
30 mg/kg every 5 h (150 mg/kg/day).
Mouse peritonitis model
This mouse peritonitis model has been previously character-
ised in our laboratory [6, 23]. Inbred, female C57BL/6 mice
(6 weeks; 14–16 g) were used (Harlan Int. Ibérica, S.A.,
Barcelona, Spain). Inoculation was performed via a 26-gauge
syringe by ip injection of 0.5 ml of the inoculum consisting
of a 5×10
8 CFU/ml staphylococcal suspension with 5% (w/
v) mucin in sterile saline. A group of control mice (n≥18)
w e r ek i l l e d4ha f t e ri n o c u l a t i o n( h o u r0 )a n da n t i b i o t i cs c
therapy was initiated. The rest of the mice were randomised
1362 Eur J Clin Microbiol Infect Dis (2010) 29:1361–1367to the control group receiving saline (n≥2 5 )o rt oo n eo f
the following therapeutic schedules (n≥10 per therapy):
linezolid, vancomycin, imipenem, linezolid+vancomycin,
linezolid+imipenem and vancomycin+imipenem, receiv-
i n gs ct r e a t m e n to v e r2 5h .A t2 5ho ft h e r a p y( 5ha f t e rt h e
last antibiotic dose), mice were anaesthetised ip with
ketamine/xylazine and peritoneal washes were performed
by injecting 2 ml of sterile saline ip followed by a massage
of the abdomen. Immediately, 0.1 ml of blood was
withdrawn by cardiac puncture and the animals were then
sacrificed by cervical dislocation. Next, the abdomen was
opened and 0.2 ml of peritoneal fluid (PF) was recovered
from the peritoneum. Undiluted and 10-fold-diluted PF
samples (0.1 ml) were plated on SBA plates to perform
bacterial determinations. Mortality was recorded after 25 h
of therapy. Blood samples were grown in tryptic soy broth
(TSB) at 37°C for 24 h and then 0.1 ml of broth was
cultured on SBA plates to assess S. aureus bacteraemia.
Antibiotic assays
Vancomycin serum concentrations were determined by
fluorescent polarisation immunoassay using a TDx analyser
(Abbott Cientifica, S.A., Diagnostics Division, Costa Brava
13, 28034 Madrid, Spain) with a detection limit of 2.0 μg/ml.
Serum concentrations of linezolid and imipenem were
measured using the agar disc diffusion method and Bacillus
subtilis ATCC 12432 and Escherichia coli ATCC 25922,
respectively, as assay organisms. Standard curves were
constructed using mouse plasma. Assay validation indicated
linearity (r
2 value) of 0.9709 for imipenem and 0.9887 for
linezolid. The detection limit was 0.5 μg/ml and 2 μg/ml for
imipenem and linezolid, respectively.
Statistics
Statistical analysis was performed with SPSS 12.0. Analysis
of variance (ANOVA) with Dunnett’s post-hoc tests was
used to analyse multiple bacterial count comparisons
between therapeutic and control groups. Two-tailed Fisher’s
exact test was used for analysing the survival and bacter-
aemia data. A p-value of <0.05 was considered to be
statistically significant.
Results
In vitro time–kill studies
Linezolid achieved a bacterial decrease of up to 2 log10CFU/ml
when tested at 4–16 mg/l against both strains. Vancomycin
achieved a bacterial decrease of 2 log10CFU/ml when studied
a t2a n d8m g / la g a i n s tt h eh G I S Aa n dt h eG I S As t r a i n ,
respectively. Imipenem failed to inhibit bacterial growth at
any tested concentration (8–64 mg/l).
In killing curves with the hGISA strain, linezolid
combined with vancomycin showed lower activity than
vancomycin alone. Vancomycin activity was decreased
between 1–1.5 log10CFU/ml at 24 h. The same combination
improved the activities of antibiotics tested alone against
the GISA strain (Fig. 1).
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Fig. 1 Time–kill curves of the combinations of linezolid plus
vancomycin that improved the activities of both monotherapies
against the GISA strain. LZD, linezolid; VAN, vancomycin
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MIC and imipenem did not improve upon the activity of
linezolid tested alone against either strain. The addition of
sub-MIC concentrations of linezolid to imipenem produced
a synergistic effect against both strains (Fig. 2).
The combination of vancomycin with imipenem was
bactericidal and synergistic against the hGISA strain.
Vancomycin tested at 2 mg/l in combination with imipenem
(8–64 mg/l) was also bactericidal and improved upon the
activity of vancomycin alone against the GISA strain.
Pharmacokinetics
The linezolid- and vancomycin-free maximum concentrations
in serum were 18.16 and 37.73 mg/l, respectively (with a
protein binding of 26% for linezolid and 25% for vancomycin
[24, 25]). The imipenem-free maximum concentration found
in serum was 38.26 mg/l. Drug serum concentrations in
humans are 12–15 mg/l for linezolid (dose 600 mg/12 h),
30–40 mg/l for vancomycin (dose 1 g/12 h) [26]a n d
32.1 mg/L (dose 500 mg/6 h) for imipenem [27].
Mortality and bacteraemia rates
In control mice, the mortality rates were 90% and 69% after
25 h of infection with the hGISA and GISA strains,
respectively. At the same time point, the mortality in mice
infected with the hGISA strain was 0% in all therapeutic
groups, except for the imipenem (20%, 2/10) and the
vancomycin plus imipenem (7%, 1/14) groups. In mice
infected with the GISA strain, the mortality was 0% in all
treated animals except for those receiving imipenem mono-
therapy (45.5%, 5/11). Data from GISA-infected animals
treated with imipenem monotherapy were not considered for
any statistical analysis because of the low number of animals
that survived after 25 h of therapy (n=6).
Bacteraemia in control animals at 0 h, expressed as a
percentage of positive blood cultures, was 100% for each
strain. Bacteraemia rates in control and therapeutic groups
after 25 h of therapy are shown in Table 1. Imipenem alone
and in combination with vancomycin failed in blood
bacterial clearance. Linezolid alone and its combinations
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Fig. 2 Time–kill curves with synergistic activity for linezolid in
combination with imipenem against hGISA and GISA strains. LZD,
linezolid; IMP, imipenem
Table 1 Bacteraemia rates of control and therapeutic groups of
infected mice after 25 h of subcutaneous therapy. Data are expressed
as percentages of positive blood cultures (n≥10 mice/group except for
imipenem against the GISA strain, where n=6). LZD, linezolid; VAN,
vancomycin; IMP, imipenem
Therapy (25h) % positive blood cultures
hGISA strain GISA strain
Control 100 100
LZD 35 mg/kg/5 h 73
a 67
a, c
VAN 60 mg/kg/5 h 93 81
IMP 30 mg/kg/5 h 100 81*
LZD + VAN 64
a, b 79
LZD + IMP 64
a, b 67
a, c
VAN + IMP 93 100
*Small n; this group was excluded from the statistical studies
ap<0.04 vs. control group
bp<0.04 vs. IMP group
cp<0.05 vs. VAN + IMP group
1364 Eur J Clin Microbiol Infect Dis (2010) 29:1361–1367significantly reduced the bacteraemia rates achieved by the
control group in hGISA-infected mice (p<0.04). Mice
treated with linezolid combinations also showed a lower
number of positive blood cultures than the imipenem-
treated group (p<0.04). In GISA-infected mice, linezolid
alone and in combination with imipenem significantly
reduced the bacteraemia rates reached by the control (p ≤
0.02) and the vancomycin plus imipenem (p<0.05) groups.
Murine peritonitis model: therapeutic efficacy
Bacterial counts in PF (mean log10CFU/ml ± SD) of control
animals at hour 0 were 8.17±0.81 for the hGISA strain (n=
25) and 7.82±0.57 for the GISA strain (n=18). Bacterial
counts in PF of control and treated mice after 25 h are
shown in Table 2. The efficacy of an antibiotic therapy was
definedasthe decreaseinthenumberofCFU(ΔlogCFU/ml)
in PF between 0 and 25 h. All regimens were statistically
more effective than the control group for both strains
(p<0.001). Linezolid monotherapy produced similar bacte-
rial decreases against both isolates. Linezolid was as
effective as vancomycin against the hGISA strain but
slightly improved upon the vancomycin activity against the
GISA strain.
Linezolid combinations showed comparable efficacies to
linezolid monotherapy against both strains. The association
of linezolid with vancomycin was more active in reducing
bacterial counts than vancomycin alone in mice infected
with the GISA strain. The addition of linezolid to imipenem
showed enhanced activity upon imipenem alone against
both strains. The association of linezolid with either
vancomycin or imipenem showed higher activity than
vancomycin plus imipenem against both strains (p=0.048,
linezolid plus vancomycin vs vancomycin plus imipenem
against the GISA strain).
Discussion
The increasing incidence of nosocomial infections due to S.
aureus antibiotic-resistant strains and the report of therapeutic
failures associated with standard glycopeptide therapy high-
light the importance of identifying new synergistic drug
combinations [1, 7, 8]. Linezolid has demonstrated good
activity against most staphylococci, including methicillin-
resistant strains [12, 13].
Linezolid was tested in vitro at achievable concentra-
tions in human serum after oral administration of 500 and
600 mg regimens [22]. At 4–16 mg/l, linezolid was
effective against both hGISA and GISA strains. Its
association with different drugs exerted distinct effects.
Linezolid combined with imipenem was synergistic against
both strains. The synergistic interaction between low
concentrations of linezolid and imipenem has been previ-
ously reported against MRSA strains [28]. An indifferent
effect was the most common result achieved with the
interaction between linezolid and vancomycin according to
previous studies involving MRSA and hGISA strains [29,
30]. Of particular interest was our finding of a synergistic
killing with sub-MIC concentrations of both antibiotics in
combination against the GISA strain. This enhanced effect
has been reported on another GISA strain in an in vitro
pharmacodynamic model [31].
In the murine peritonitis model caused by the hGISA
strain, no differences were found between linezolid and
vancomycin monotherapies in terms of bacterial counts in
peritoneal fluid and survival. In contrast, in GISA-infected
mice, linezolid showed a slightly higher activity than
vancomycin, although this did not reach statistical signif-
icance. Moreover, linezolid achieved higher percentages of
blood culture sterilisation in comparison to vancomycin
against both isolates. The use of combined regimens would
be a good approach to improve the effectiveness of
linezolid in the management of drug-resistant infections.
In our experimental setting, the addition of linezolid to
vancomycin showed similar efficacy but decreased the
bacteraemia rates in comparison to vancomycin and line-
zolid monotherapies against the hGISA strain. The same
combination enhanced vancomycin activity against the
GISA strain but did not improve the rates of blood
sterilisation achieved with monotherapy regimens.
Even though β-lactam antibiotics do not show any activity
against MRSA and hGISA strains, their use in combination
with linezolid has been shown to be highly effective against
MRSA strains in vitro and in experimental endocarditis [28].
In our study, linezolid combined with imipenem was an
effective therapy in mice infected with hGISA/GISA strains
in terms of bacterial and bacteraemia reduction.
Our study found some discrepancies between in vitro
and in vivo results. It should be emphasised that in vitro
Table 2 Bacterial counts in peritoneal fluid (PF) for therapeutic and
control groups after 25 h of subcutaneous therapy
Therapy (25h) PF bacterial counts ± SD (log CFU/ml) [n]
hGISA strain GISA strain
Control 8.19±0.57 [29] 8.29±0.9 [29]
LZD 35 mg/kg/5 h 5.88±0.61 [15]
a 5.60±0.61 [18]
a, b
VAN 60 mg/kg/5 h 5.90±0.31 [14]
a 6.02±0.56 [16]
a
IMP 30 mg/kg/5 h 6.40±0.80 [10]
a 7.38±1.38 [6]*
LZD + VAN 5.94±0.30 [14]
a 5.61±0.56 [14]
a, b
LZD + IMP 5.81±0.41 [14]
a 5.74±0.52 [15]
a
VAN + IMP 6.15±0.68 [14]
a 6.28±0.49 [14]
a
*Small n; this group was excluded from the statistical studies
ap<0.001 vs. control group
bp<0.05 vs. VAN + IMP group
Eur J Clin Microbiol Infect Dis (2010) 29:1361–1367 1365interaction may not translate into clinical efficacy, mainly
because of the diversity of mechanisms involved in in vivo
antibiotic interactions which cannot be analysed by the use of
in vitro techniques [33]. Indeed, experts recommend to use
the in vivo efficacy more than the in vitro data when selecting
an anti-staphylococcal drug as a therapeutic option [34].
To date, few studies have addressed the role of linezolid
combinations against glycopeptide-resistant S. aureus. The
present study confirms the anti-staphylococcal activity of
linezolid in association with vancomycin or imipenem,
indicating that linezolid combinations preserve the activity
of linezolid alone and might be considered as therapeutic
options in the management of infections caused by S.
aureus strains with reduced susceptibility to glycopeptides.
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